# Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

> **NCT02329769** · PHASE2 · TERMINATED · sponsor: **BioMarin Pharmaceutical** · enrollment: 15 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** PRO044 SC 6 mg/kg
- **DRUG:** PRO044 IV 6 mg/kg
- **DRUG:** PRO044 IV 9 mg/kg

## Key facts

- **NCT ID:** NCT02329769
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2016-07-01
- **Final completion:** 2016-08-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02329769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02329769, "Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02329769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*